Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | THRA | P10827 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1848320 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL10569325 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL5807045 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL2048536 | 0.88 | — | — | |
| SCHEMBL6749100 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL3002424 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL1847927 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL6031279 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL997470 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A | |
| SCHEMBL6753110 | 0.88 | CYP1A2 (0.59) | CYP1A2EPHX1HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-2056675-B1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS LLC (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2018-11-22 | — | — | US | disclosed |
| EP-3287464-A1 | ONE POT SYNTHESIS OF TETRAZOLE DERIVATIVES OF SIROLIMUS | Abbott Laboratories (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9855279-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2018-01-02 | — | — | US | disclosed |
| EP-2859916-B1 | Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy | GALERA LABS LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-5637578-A | AGENTS FOR INFLAMMATION, ISCHEMIC/REPERFUSION INJURY, STROKE, ATHEROSCLEROSIS, AND HYPERTENSION | MONSANTO COMPANY | 1997-06-10 | — | — | US | disclosed |
| US-5610293-A | TREATMENT OF INFLAMMATORY DISEASES, ISCHEMIC/REPERFUSION INJURY, STROKE, ATHERSCLEROSIS, HYPERTENSION | MONSANTO COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1997006831-A1 | METHODS OF DIAGNOSTIC IMAGE ANALYSIS USING METAL COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| WO-1997006824-A2 | BIOCONJUGATES OF MANGANESE COMPLEXES AND THEIR APPLICATION AS CATALYSTS | MONSANTO COMPANY (US) | 1997-02-27 | — | — | WO | disclosed |
| WO-1995028968-A1 | DIAGNOSTIC IMAGE ANALYSIS WITH METAL COMPLEXES | MONSANTO COMPANY (US) | 1995-11-02 | — | — | WO | disclosed |
| EP-0421441-B1 | Pantothenic acid derivatives | FUJIREBIO KK (JP) | 1995-01-25 | — | — | EP | disclosed |
| WO-1994015925-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| US-5120738-A | Cardiovascular disorders | FUJIREBIO INC. (JP) | 1992-06-09 | — | — | US | disclosed |
| EP-0421441-A2 | Pantothenic acid derivatives | FUJIREBIO INC. (JP) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180333421-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CYP1A2 2277/4885EPHX1 3572/4885HTT 3971/4885 |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CYP1A2 2277/4885EPHX1 3572/4885HTT 3971/4885 |
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | LPO, SOD3, MPO | CYP1A2 2277/4885EPHX1 3572/4885HTT 3971/4885 |
| US-10610533-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | CYP1A2 2277/4885EPHX1 3572/4885HTT 3971/4885 |
| US-11612608-B2 | Methods of treating oral mucositis | LPO, SOD3, MPO | CYP1A2 2277/4885EPHX1 3572/4885HTT 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.